Novel Pharmacologic Treatments of Female Sexual Dysfunction.
How. Andrew A; Jowdy. Christopher C; Novatcheva. Elli E; Clayton. Anita H AH
Key Findings
- Bremelanotide (pt‑141) improves desire in women with hypoactive sexual desire disorder within a few hours of a single subcutaneous dose.
- Common side effects include nausea, flushing, and a temporary rise in blood pressure, usually mild and short‑lived.
- Flibanserin requires daily dosing and takes weeks to show effect, while bremelanotide offers rapid, on‑demand use.
- Patient selection (e.g., premenopausal women without uncontrolled hypertension) and proper counseling are crucial for success.
Practical Outcomes
- For biohackers interested in self‑experimentation, bremelanotide can be used as a 1.75 mg subcutaneous injection taken about 45 minutes before sexual activity. Monitor blood pressure and watch for nausea; avoid use if you have uncontrolled hypertension or are on certain serotonergic drugs. This protocol offers a quick, reversible way to test libido enhancement without daily medication.
Summary
The review shows that the peptide bremelanotide (pt‑141) is an FDA‑approved, on‑demand injection that can boost sexual desire in women with low libido, working faster than daily pills like flibanserin. It also outlines safety tips and who might benefit most.
Abstract
This review evaluates pharmacologic treatments for female sexual dysfunction (FSD), focusing on hypoactive sexual desire disorder (HSDD). We provide clinically relevant applications for Food and Drug Administration (FDA)-approved medications (flibanserin and bremelanotide) and investigational therapies (Lorexys and testosterone combinations). Detailed study outcomes, safety profiles, and clinical strategies guide clinicians in appropriate diagnosis, patient selection, expectation setting, side effect management, and patient education, improving treatment outcomes and patient satisfaction.
Study Information
pubmed
2025
2025-01-23T00:00:00.000Z
10.1097/grf.0000000000000922
2
34